Poster Abstracts • OFID 2017:4 (Suppl 1) • S377 and AmpC), and aztreonam (ATM) is a monobactam stable to hydrolysis by metallo-β-lactamases (MBL).
Background. Meropenem-vaborbactam (MER-VAB) is a carbapenem-β-lactamase inhibitor combination with enhanced activity against KPC-producing
Enterobacteriaceae recently evaluated in a phase 3 clinical trials for cUTIs and infections due to CRE. We analyzed the activity of MER-VAB against 517 isolates carrying bla KPC collected worldwide during 2014-16.
Methods. Enterobacteriaceae isolates (n = 34,069) from 34 countries were susceptibility (S) tested by reference broth microdilution method for MER-VAB (at fixed 8 µg/mL) and comparators. Carbapenem-resistant Enterobacteriaceae (CRE; CLSI criteria) were submitted to PCR/Sanger sequencing or next-generation sequencing for bla KPC screening.
Results. A total of 517 (1.5%) carried bla KPC and 6 variants were observed: 293 bla KPC-3 , 218 bla KPC-2 , 2 bla KPC-4 , 2 bla , and 1 each of bla KPC-2 -like and bla . Isolates were mainly K. pneumoniae (437), but also 32 E. cloacae, 13 K. oxytoca, 12 E. coli, 12 S. marcescens, and 4 other species. Isolates carrying bla KPC were detected in 17 countries. The occurrence ranged from <0.1% to 11.3%, being higher in Brazil, Italy (9.3%), Poland (5.6%), and Argentina (5.2%). MER-VAB inhibited 514/517 (99.4%) isolates carrying bla KPC at ≤8 µg/mL and this compound was the most active agent tested against these isolates (MIC 50/90 , 0.12/1 µg/mL). Three isolates displaying elevated MER-VAB MIC values (>8 µg/mL) co-harbored bla NDM-1 or bla OXA-48 -like in addition to bla KPC or had a missense mutation on OmpK35. MER alone (MIC 50/90 , 32/>32 µg/mL), imipenem (MIC 50/90 , >8/>8 µg/mL), and doripenem (MIC 50/90 , >4/>4 µg/mL) were not active against isolates harboring bla KPC . Amikacin (MIC 50/90 , 16/>32 µg/mL) and gentamicin (MIC 50/90 , 2/>8) µg/mL inhibited only 54.9% and 57.3% of the isolates (CLSI breakpoint). Colistin (MIC 50/90 , ≤0.5/>8 µg/mL; 70.4% S/EUCAST breakpoint) and tigecycline (MIC 50/90 , 0.5/1 µg/mL; 99.4% S/US FDA criteria) were the most active comparators.
Conclusion. The occurrence of bla KPC is still low overall, but can be as high as 5-10% in a few countries and occur in species other than Klebsiella. KPC-producers are highly resistant to available antimicrobial agents and MER-VAB will be a useful alternative to treat infections caused by these organisms. Background. Plazomicin (PLZ) is a next-generation aminoglycoside (AMG) stable against aminoglycoside-modifying enzymes (AME) that completed Phase 3 studies for complicated urinary tract infections and serious infections due to carbapenem-resistant Enterobacteriaceae (ENT). We evaluated the activity of PLZ and AMGs against ENT collected in US hospitals during 2016.
Methods. A total of 2,097 ENT were susceptibility (S) tested by CLSI reference broth microdilution methods. E. coli, Klebsiella spp. Enterobacter spp., and P. mirabilis isolates displaying non-S MICs (CLSI criteria) for gentamicin (GEN), amikacin (AMK), and/or tobramycin (TOB) were submitted to WGS, de novo assembly and screening for AME genes.
Results. Against ENT, PLZ was more active than all 3 clinically available AMGs (Table) . PLZ and AMK activities were stable regardless of the infection type; however, differences were observed for GEN and TOB. Bloodstream isolates displayed higher GEN MICs when compared with the other infection sites. TOB activity varied 4-fold, being higher for bloodstream and pneumonia infections and lower for skin/soft tissue and other/unknown specimens. Against 198 isolates carrying 1 or more AMEencoding genes detected among 208 AMG-non-S isolates, the activity of PLZ was 8-to 16-fold greater when compared with the activity of AMK and at least 16-fold higher than the activity of GEN or TOB.
Conclusion. PLZ was active against ENT isolates from US hospitals regardless of infection type. PLZ displayed activity against isolates carrying AME genes that represent 12.0% of selected species. AME-carrying isolates were considerably more resistant to AMK, GEN, and TOB, highlighting the potential value of PLZ to treat infections caused by these organisms.
